One-Year Results from the Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced continued positive results from ABSORB, the world's first clinical trial evaluating the safety and performance of a fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease.
Abbott Named to Science Magazine's List of Top Employers
- Details
- Category: Abbott
For the fifth consecutive year, Abbott (NYSE: ABT) has been named among the top 20 employers in the Science magazine 2007 Top Biotech and Pharma Employer's survey.
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
- Details
- Category: Pfizer
Pfizer Inc said that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The calcium salt patent expires in July 2010.
Novartis delivers record earnings in first nine months of 2007
- Details
- Category: Novartis
Strong operational performance for Group continuing operations:
- Nine-month net sales up 13% to USD 28.1 billion (+9% local currencies) driven by all divisions, particularly Vaccines and Diagnostics and Sandoz
- Operating income rises 9% to USD 6.5 billion, excluding a one-time incremental environmental provision of USD 590 million to cover worldwide remediation plans
Strong sales growth in the first nine months of 2007
- Details
- Category: Roche
Group sales up 12% in local currencies to 33.9 billion Swiss francs. As anticipated, Tamiflu sales decline significantly in third quarter following completion of outstanding pandemic stockpiling orders. Full-year outlook reaffirmed: Group and Pharmaceuticals Division anticipate double-digit sales increases, and both divisions expect above-market growth; target is for Core Earnings per Share to grow faster than Group sales.
Pfizer Reports Third-Quarter 2007 Results
- Details
- Category: Pfizer
Third-Quarter 2007 Reported Diluted EPS of $0.11 Represents a Decline of 76% Compared to the Same Period Last Year and Includes Charges of $0.31 ($2.8 Billion Pre-Tax) Related to a Decision to Exit Exubera.
Adjusted Diluted EPS of $0.58 for the Third-Quarter 2007 Represents an Increase of 7% Compared to the Same Period a Year Ago.
Adjusted Diluted EPS of $0.58 for the Third-Quarter 2007 Represents an Increase of 7% Compared to the Same Period a Year Ago.
Novel agent for treatment of cerebral stroke and other diseases with neuronal damage
- Details
- Category: Lundbeck
H. Lundbeck A/S has initiated phase I clinical trials with the pharmaceutical candidate Lu AA24493 to investigate safety, tolerability and the pharmacokinetic profile of the compound in patients suffering from acute ischemic stroke.
More Pharma News ...
- Abbott Reports 14.4 Percent Sales Growth in Third Quarter
- Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
- Three-year analysis demonstrates continued robust treatment effect of Alemtuzumab compared to Rebif
- Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care
- Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
- Boehringer Ingelheim distinguished as number one Top Employer 2007 by Science Magazine
- Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine